KnowTheStock
Log inCreate free account

Alkermes plc

ALKS
Research and Development in Biotechnology (except Nanobiotechnology) · NASDAQ
$52.53last close · market cap 9.11 Billion
Compare with…
53.8SCORE / 100
Our verdictSELLModerate Growth but Declining, Stock Price Very HighQtr Ending 2026-06-30 · trend negative

Why Sell

Balance sheet is strong; income statement and cash flow are moderate.

Next earnings: 2026-11-03 (BMO), EPS Forecast: ($0.08)

What is strong
  • Revenue Growth is 10.79%
  • Current Asset to Current Liability Ratio is 2.3
  • Total Debt to Total Assets Ratio is 0.34
What to watch
  • Operating Income Growth is -68.67%
  • Net Income Growth is -81.02%
  • Earnings Per Share (EPS) Growth is -81.73%
  • Net Margin is 3.97%
  • Debt Ratio is 0.59
  • Current Debt to Net Income Ratio is 52.89
  • Cash from Operations Growth is -51.79%
  • Capital Expenditure is High
  • Net Increase in Cash is Negative
  • Investment Risk is High

What changed

Score by quarter

Downgraded from Hold to Sell in the Mar 2026 quarter: 64.3 → 53.9 (-10.4). This quarter: -0.1.

203040506070Sep 2022Jun 2026

What the score is made of

Income statement42.6 +0.5
Balance sheet78.1 +0.0
Cash flow47.7 -2.6

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)1.67 Billion10.79 % growth
EPS0.38-81.73 % growth
Profit margin3.97 %Profit per $1 of sales
P-E ratio—Not available
Market cap9.11 BillionShares × price
Debt-equity ratio0.83Leverage
Dividend0.00Per share, annual
Next earnings2026-11-03BMO · EPS forecast ($0.08)
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About Alkermes plc

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

CEO
Richard F. Pops
Employees
2,482
Sector
Professional, Scientific, and Technical Services
Exchange
NASDAQ
alkermes.com

Similar stocks

Loading…